Vishwas Seshadri
About Vishwas Seshadri
Vishwas Seshadri is the CEO and Director with a strong background in microbiology, immunology, molecular biology, and finance, known for his leadership in the development of novel therapies in hematology and oncology.
CEO and Director Vishwas Seshadri
Vishwas Seshadri currently holds the positions of Chief Executive Officer and Director. His leadership roles encompass overseeing strategic direction and organizational growth. His responsibilities likely include guiding company policies, managing executive teams, and directing business operations to meet set objectives. He brings a wealth of experience in biotechnology, healthcare, and finance, which supports his effectiveness in these high-level roles.
Educational Background of Vishwas Seshadri
Vishwas Seshadri completed his Ph.D. in Microbiology, Immunology & Molecular Biology. He further advanced his academic expertise with a post-doctoral fellowship in epigenetics at the University of Arizona. Recognizing the importance of business acumen in managing scientific endeavors, he earned an M.B.A. in Finance and Healthcare from the Wharton School of the University of Pennsylvania. This blend of scientific and business education positions him uniquely for leading roles in the biotechnology sector.
Professional Experience of Vishwas Seshadri
Vishwas Seshadri has amassed significant professional experience in the biotechnology and pharmaceutical industries. At Celgene Corporation, he focused on the development and commercialization of novel therapies in hematology and oncology. He was instrumental in leading the team responsible for the launch of Breyanzi, an autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy. In addition, he served as Head of Early-Stage Upstream Process Development for Biologics at Dr. Reddy's Laboratories, contributing to essential processes in biologics development.
Leadership Role in Launching Breyanzi
Vishwas Seshadri played a pivotal role in the launch of Breyanzi, an autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy. His leadership in this project at Celgene Corporation involved overseeing development strategies and ensuring successful commercialization. This role highlights his ability to lead innovative healthcare solutions from conceptual stages through to market introduction, underlining his expertise in managing complex product launches in the biotechnology sector.